With the development of glioma mechanism research and clinical treatment, some prognostic factors have been well-characterized, including WHO grade, isocitrate dehydrogenase (IDH) status, and 1p/19q codeletion status. The gene discussed is IDH1; the disease is central nervous system cancer.